Allergy

A large specialty pharmacy cohort supports sustained reductions in attack rates across HAE subtypes, including normal C1 inhibitor disease.

Updated international guidance reinforces early self-administered on-demand therapy and integrates newer kallikrein-targeted agents into routine HAE management.

Real world study shows significant 12- and 18-month attack rate reductions across HAE subtypes and baseline severities following berotralstat initiation.

A new study found no association between antibiotic class or number of classes in infancy and later allergic disease, reinforcing stewardship over substitution.

Valenta discusses how seasonal allergen exposure selectively boosts IgE production through plasmablast recall, without a coordinated IgG response.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

Upstream Bio announced positive topline results from the phase 2 VALIANT trial evaluating the efficacy and safety of verekitug in adults with severe asthma.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

Vaginal delivery, exclusive breastfeeding, and early sibling exposure strongly predicted colonization with bifidobacteria that suppress IgE responses in a recent study.

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.

Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children.